Litigation Details for Local No. 1 Health Fund v. Biogen, Inc. (N.D. Ill. 2024)
✉ Email this page to a colleague
Local No. 1 Health Fund v. Biogen, Inc. (N.D. Ill. 2024)
Docket | ⤷ Sign Up | Date Filed | 2024-08-16 |
Court | District Court, N.D. Illinois | Date Terminated | |
Cause | 15:1 Antitrust Litigation | Assigned To | Franklin Ulyses Valderrama |
Jury Demand | Plaintiff | Referred To | |
Patents | 8,399,514 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Local No. 1 Health Fund v. Biogen, Inc.
Details for Local No. 1 Health Fund v. Biogen, Inc. (N.D. Ill. 2024)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2024-11-01 | 27 | Amended Complaint | manufacturers for infringement of U.S. Patent No. 8,399,514 (“’514 Patent”) because they had filed ANDAs seeking…challenges to its patent on Tecfidera. These patent challenges threatened Tecfidera’s patent protections,…profits because it had a patent on Tecfidera. 4. But that patent was very weak. Beginning…validity of the Tecfidera patent. Biogen knew that once it lost those patent lawsuits its Tecfidera sales…when the courts hearing the patent cases ruled that the Tecfidera patent was invalid, the generic manufacturers | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |